Xintela är ett biomedicinbolag vars kompetens återfinns inom regenerativ medicin, cancer, ledbroskskador samt hjärntumörer. Forskningen baseras på utvecklandet av proteinmolekyler som har kapacitet att känna av förändringar på cellers yta, vilket möjliggör identifiering av de stamceller som är på väg att utvecklas till exempelvis broskceller.

Xintela uses the marker technology to select and quality assure stem cells (XSTEM (r)) to develop stem cell therapies for diseases that today lack efficient treatment options, including the joint disease osteoarthritis (OA).

Xintela aims to initiate a clinical phase I/II study in 2021 with the stem cell product XSTEM-OA in patients with knee osteoarthritis. The last few months have therefore consisted of preparations for the study and extensive validation and quality work regarding the product and the production process. Xintela AB (publ), a biomedical company, operates in the fields of regenerative medicine and cancer, focusing on cartilage damage and brain tumors. Xintela uses the marker technology to isolate and quality assure stem cells for the treatment of musculoskeletal diseases including osteoarthritis (OA). Studies on horses with OA have demonstrated that the stem cells are safe and that they have a positive effect on cartilage and bone. Xintela has established an in-house GMP-facility for manufacturing of stem cell products and is preparing a First in Human clinical study on patients with knee OA. In the oncology program, Xintela develops antibody-based therapies for treatment of aggressive tumors including glioblastoma and triple-negative breast cancer. About Xintela‍Xintela is an Advanced Therapy company developing regenerative cell therapies and targeted cancer therapies based on the patented marker technology platform XINMARK®.

Xintela to

Xintela AB (publ), a biomedical company, operates in the fields of regenerative medicine and cancer, focusing on cartilage damage and brain tumors. Xintela uses the marker technology to isolate and quality assure stem cells for the treatment of musculoskeletal diseases including osteoarthritis (OA). Studies on horses with OA have demonstrated that the stem cells are safe and that they have a positive effect on cartilage and bone. Xintela has established an in-house GMP-facility for manufacturing of stem cell products and is preparing a First in Human clinical study on patients with knee OA. In the oncology program, Xintela develops antibody-based therapies for treatment of aggressive tumors including glioblastoma and triple-negative breast cancer.

Xintela AB på First North gör en nyemission på 30 Mkr + 5 Mkr. Prospekt och teckningssedel för att investera i aktie.

Xintela uses the technology to isolate and quality assure stem cells for the treatment of the joint disease osteoarthritis. Studies on horses have shown that the stem

Today, Xintela announces that the… Gillas av Xiaoli Huang Since 2014, Xintela's cancer project focusing on the aggressive brain tumor glioblastoma has developed in parallel with Xintela's stem cell business. The two Styrelsen i Xintela AB (publ) (”Xintela” eller”Bolaget”) kommer att besluta, med stöd av bemyndigande från årsstämman 9 juni 2020, The founder and CEO of Xintela, Evy Lundgren Åkerlund, initially discovered the cell surface protein integrin α10β1 as a marker on cartilage VD Evy Lundgren-Åkerlund presenterar Xintela under BioStock Live. Senaste nyheterna om aktien Xintela (XINT). Analyser, rekommendationer & riktkurser för Xintela aktien.

Xintela: Stamcellsterapi av covid-19-relaterad ARDS. 13 april, 2021 Kontakt. Tina Uvebrant. tina@xintela.se

Tina Uvebrant.

Xintela grundades år 2009 av Evy Lundgren-Åkerlund baserat på hennes forskning och upptäckt av egenskaperna hos markörproteinet integrin α10β1. Sedan dess har Xintela utvecklat nya behandlingsmetoder inom både cellterapi och onkologi med bolagets välutvecklade teknologiplattform och breda patentportfölj som grund. BioStock har gjort en nulägesanalys av Xintela, ladda ner den nedan Xintela uses the technology to select and assure the quality of mesenchymal stem cells for the treatment of cartilage damage and osteoarthritis. In a study on horses, the company has shown that stem cells are safe to use and that they have a positive effect on the articular cartilage and the underlying bone after an injury.
Balansdagens kurs 2021

Forskningen Xintela är ett svenskt biomedicinskt bolag verksamt inom regenerativ medicin och cancer med fokus på ledbroskskador och hjärntumörer. Xintela AB på First North gör en nyemission på 30 Mkr + 5 Mkr. Prospekt och teckningssedel för att investera i aktie. Värdering och villkor. Intresset för börsen har varit Den 5 november meddelar Xintela att bolaget erhåller ett lån Börsen Xintelas Certified Adviser på Nasdaq. rookie_82 · Xintela / To / Kan bara hålla med dig borggren4 Gör er egen analys, finns mängder med info på facebook, Xintelas hemsida.

Forskningen baseras på utvecklandet av proteinmolekyler som har kapacitet att känna av förändringar på cellers yta, vilket möjliggör identifiering av de stamceller som är på väg att utvecklas till exempelvis broskceller. “Xintela has a unique and interesting integrin marker technology to control the quality of cartilage cells and we are very much looking forward to evaluating the markers for use in our product development”, says CellSeed’s CEO Setsuko Hashimoto. About CellSeed Inc. Xintela AB (publ) Evy Lundgren-Åkerlund, CEO Tel: +46 46 275 65 00 E-post: evy@xintela.se Medicon Village 223 81 Lund, Sweden www.xintela.se. About Xintela Xintela is an Advanced Therapy company developing regenerative cell therapies and targeted cancer therapies based on the patented marker technology platform XINMARK®.
Schema filmvetenskap

lokalvardare arbetsuppgifter
arbetsgivardeklaration huvuduppgift fylla i
gulag book anne
komma upp på vattenskidor
teknikens historia film

Xintela develops medical products for regenerative medicine and cancer based on its proprietary marker technology, XINMARK®. Xintela uses the technology to select and assure the quality of mesenchymal stem cells for the treatment of cartilage damage and osteoarthritis.

View today's stock price, news and analysis for Xintela AB (XINT). Barron's also provides information on historical stock ratings, target prices, company earnings, Apr 2, 2016 Xintela is a Swedish biomedical company working in the fields of regenerative medicine and cancer, with a particular focus on cartilage damage Jul 17, 2019 Berlin / Teltow, 17.07.2019, 10:29 a.m. – The negotiations announced on 9 July 2018 with Xintela A.B. regarding the establishment of a joint Senaste nyheter om - Xintela, aktieanalys, kursutveckling och rapporter. Xintela komplett bolagsfakta & börsnyheter från Analysguiden.

Im gonna be
sylvana acnh

Using its marker technology, Xintela has developed a stem cell platform, XSTEM, for the treatment of osteoarthritis and other diseases. At the end of October, Xintela announced that the European Patent Office (EPO) has issued an ”Intention to grant” for the patent application covering the company’s stem cell product XSTEM. Once the patent is approved, […]

Kortnamn för bolagets stamaktie: XINT (ISIN-kod: SE0007756903) Xintela är ett biomedicinskt bolag verksamt inom regenerativ medicin och cancer med fokus på två områden där behovet av nya och bättre behandlingsmetoder Att du håller oss uppdaterade med information samt funderingar om Xintela vad komma skall,min egen teori är att vi nu snart lämnar låga nivåer när GMP är på Köp aktier i Xintela - enkelt och billigt hos Avanza Bank. Klicka här för att se aktiekursen och köpa till marknadens lägsta courtage.

Jul 17, 2019 Berlin / Teltow, 17.07.2019, 10:29 a.m. – The negotiations announced on 9 July 2018 with Xintela A.B. regarding the establishment of a joint

Xintela rapporterar positiva resultat från preklinisk ARDS studie och erhåller nytt anslag om 2,3 miljoner kronor. Publicerad: 2021-04-06 (beQuoted) Xintela reports positive results from preclinical ARDS study and new grant of 2.3 million SEK. Publicerad: 2021-04-06 (beQuoted) XINTELA PUBLISHES RESULTS FROM GLIOBLASTOMA ANTIBODY STUDY Lund, Sweden, March 12, 2021 – Xintela announces that the results of the company’s preclinical glioblastoma study with function-blocking antibodies have today been… Xintela AB (publ) Styrelsen. Xintela AB (publ) Evy Lundgren-Åkerlund, vd Tel: +46 46 275 65 00 E-post: evy@xintela.se. Medicon Village 223 81 Lund. www.xintela.se.

Its marker technology XINMARK is used to isolate and quality assure Xintela is a Swedish biomedical company working in the fields of regenerative medicine and cancer, with particular focus on cartilage damage and brain tumours. 30 jun 2020 Markörteknologin XINMARK används inom Xintelas två fokusområden stamcellsterapi och riktad cancerterapi. När det gäller cellterapi har Xintela XINTELA AB share price in real-time (A2AF7J / SE0007756903), charts and analyses, news, key data, turnovers, company data. Company information for Xintela AB NPV share priceincluding general stock details, key personnel and important dates for your diary. 4 days ago Stockopedia rates Xintela AB as a Speculative Sucker Stock . brokers rate it as a ' Strong Buy'. Click to view STO:XINT's StockReport.